STM JOURNALS

Research & Reviews: A Journal of
Pharmacology

https://journals.stmjournals.com/rrjop

ISSN: 2230-9861 (Online)
ISSN: 2349-1299 (Print)
Volume 15, Issue 2, 2025
May–August
DOI (Journal): 10.37591/RRJoP

Review RRJoP

Pharmacogenomics in Anesthesia: Case Studies and Clinical Applications for Personalized Care

Tehseen Irshad[1,*], Bilal[2], Sowby Jan[1]

Abstract

Pharmacogenomics, the study of how genetic variability influences individual responses to medications, is transforming anesthetic practice by enabling personalized care. This case study collection explores the integration of pharmacogenomic insights into anesthesia management, highlighting its impact on safety, efficacy, and patient outcomes. Adverse reactions to anesthetics often arise from genetic polymorphisms that alter drug metabolism or sensitivity. For instance, patients with RYR1 mutations are susceptible to malignant hyperthermia (MH) when exposed to volatile anesthetics like isoflurane. Case studies demonstrate how rapid intervention with dantrolene can mitigate life-threatening crises. Similarly, genetic variations in GABRG2 and CYP2D6 influence recovery times and opioid metabolism, requiring tailored anesthetic regimens. Detailed analyses of personalized approaches further underscore the value of pharmacogenomics. Adjusted propofol dosing based on UGT1A9 polymorphisms prevented prolonged sedation in a high-risk patient, while selecting alternative opioids, like hydromorphone, for a CYP2D6 poor metabolizer enhanced pain control without side effects. The use of rocuronium instead of succinylcholine for a patient with BCHE gene variants averted prolonged paralysis, showcasing precision in neuromuscular blockade management. Beyond drug selection, pharmacogenomic data guided antiemetic therapy, reducing postoperative nausea and vomiting (PONV) in patients with HTR3A polymorphisms. By tailoring interventions to individual genetic profiles, anesthesiologists ensured improved patient comfort and satisfaction. This collection also includes appendices on genetic testing workflows, dosing guidelines, and ethical considerations, providing a comprehensive framework for integrating pharmacogenomics into clinical practice.

Keywords: Pharmacogenomics, personalized anesthesia, genetic polymorphisms, adverse reactions, precision medicine

INTRODUCTION

One of the daily challenges faced by clinical anesthesiologists is the significant variability in how patients respond to a specific dose of analgesic medications. This variability is multifactorial, but considerable research has been conducted in molecular medicine to predict clinical responses based on a patient's unique DNA profile [1]. This area of study, known as "pharmacogenomics," encompasses pharmacokinetics and pharmacodynamics with the aim of developing "personalized medicine" that customizes treatment according to an individual's genetic signature.

***Author for Correspondence**
Tehseen Irshad
E-mail: mirtehseen03@gmail.com

[1]Assistant Professor, St. Soldier Group of Institutions, Jalandhar, Punjab, India.
[2]Anaesthesiologist, GMC Baramullah, Jalandhar, Punjab, India.

Received Date: February 06, 2025
Accepted Date: April 1, 2025
Published Date: April 23, 2025

Citation: Tehseen Irshad, Bilal, Sowby Jan. Pharmacogenomics in Anesthesia: Case Studies and Clinical Applications for Personalized Care. Research & Reviews: A Journal of Pharmacology. 2025; 15(2): 85–91p.

METHODS

This review evaluated current literature on pharmacogenomics in the context of analgesics used in anesthesiology practice. A systematic search was conducted on PubMed, Google Scholar, and the Cochrane Database in May 2016 using the keywords "Pharmacogenomics," "Anesthesia," "CYP polymorphism," and "metabolizers." The

search yielded 165 titles and abstracts. To ensure relevance, only human studies published in English were included, excluding letters, commentaries, editorials, and case reports. In total, 84 articles were reviewed, focusing on literature related to CYP polymorphisms and analgesics. No formal inclusion or exclusion criteria, aside from those stated, were applied.

The variations in genotypes associated with CYP polymorphisms result in distinct clinical pain.

Pharmacokinetics – Prodrug Activation

Codeine

Codeine, a prodrug, is metabolized by the enzyme CYP2D6 (a subtype of cytochrome P450) into morphine [2–5], which has 200 times greater affinity for the mu-opioid receptor than codeine. CYP2D6 is highly polymorphic, with over 100 identified alleles, leading to varying enzyme activities. Patients with two nonfunctioning alleles exhibit poor metabolism, while those with one or two functional alleles have normal (extensive) metabolism. Duplicated or promoter-function alleles result in ultrarapid metabolism, producing elevated levels of active metabolites (e.g., morphine) and heightened risk of opioid side effects like respiratory depression.

Case reports highlight serious risks associated with ultrarapid metabolism, including life-threatening intoxication, respiratory depression, and fatalities following codeine use, particularly in children and breastfeeding infants [6]. Consequently, the FDA issued a Black Box Warning for codeine use in pediatric patients after adenotonsillectomy and in breastfeeding mothers. The Clinical Pharmacogenetics Implementation Consortium has also published guidelines for codeine genotyping and prescription.

Tramadol

Tramadol, another prodrug, is converted by CYP2D6 into its active metabolite, O-desmethyltramadol, which exhibits mu-opioid receptor activity. Patients with ultrarapid metabolism exhibit greater pain relief but increased risk of side effects, while poor metabolizers may experience limited analgesic effects. Clinical outcomes vary depending on pain severity and individual metabolic capacity, with contrasting results in surgical and experimental settings.

Pharmacokinetics – Drug Elimination

Opioids

Several opioids undergo metabolism via CYP enzymes for elimination. Variants in CYP3A5 and CYP3A4 enzymes have been associated with altered drug plasma levels and side effect profiles, such as increased fentanyl concentrations and central nervous system effects [7]. Hydrocodone and morphine also exhibit genotype-dependent metabolism, with polymorphisms influencing drug efficacy and clearance.

NSAIDs

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen and celecoxib are metabolized by CYP2C8 and CYP2C9 enzymes. Variants, like CYP2C9*3, can reduce drug clearance, potentially increasing side effects like gastrointestinal bleeding. However, findings remain inconsistent, particularly for rare mutations.

Pharmacokinetics – Transmembrane Transport

The ABCB1 gene encodes P-glycoprotein (PGP), which regulates opioid transport to and from target receptors. A single nucleotide polymorphism (C3435T) reduces PGP activity, increasing opioid concentrations at receptor sites and improving analgesic efficacy. However, this SNP is also linked to heightened risk of opioid-induced respiratory depression in some populations. Studies on ABCB1 variations and postoperative pain have produced mixed results.

Pharmacodynamics – COMT

Catechol-O-methyltransferase (COMT) degrades catecholamines. A common variant (val158met)

reduces COMT activity, elevating dopamine levels and suppressing endogenous opioid production, which increases opioid receptor availability [8]. This variant has been associated with variable opioid requirements for postoperative and cancer pain, though haplotype studies provide more comprehensive insights.

Pharmacodynamics – Mu-Opioid Receptor

The OPRM1 gene encodes the mu-opioid receptor and is highly polymorphic. The A118G SNP has been extensively studied, with conflicting results regarding pain sensitivity and opioid requirements. While some studies suggest that A118G homozygotes require higher opioid doses, others report the opposite or no significant differences [9]. A large-scale study of cancer pain treatment in 2,294 patients found no significant association between 112 SNPs from 25 genes and opioid dose requirements.

CASE STUDIES ON ADVERSE REACTIONS

Case studies highlight the clinical implications of genetic variability in response to volatile anesthetics. For example, patients with polymorphisms in the RYR1 gene, which encodes the ryanodine receptor, are at risk for malignant hyperthermia (MH) when exposed to volatile anesthetics like isoflurane and sevoflurane. MH is a life-threatening condition characterized by hypermetabolism, muscle rigidity, and hyperthermia.

- *Case Study 1: Malignant Hyperthermia with Isoflurane:* A 45-year-old male undergoing elective surgery developed sudden hyperthermia, muscle rigidity, and acidosis after induction with isoflurane. Genetic testing revealed a mutation in the RYR1 gene [10], confirming the diagnosis of MH. Immediate discontinuation of isoflurane and administration of dantrolene, a muscle relaxant, successfully managed the crisis.
- *Case Study 2: Prolonged Recovery with Sevoflurane:* A 30-year-old female experienced prolonged emergence and delayed recovery after anesthesia with sevoflurane. Genetic analysis identified polymorphisms in the GABRG2 gene, suggesting altered sensitivity to sevoflurane. Adjustments in the anesthetic regimen for future surgeries, including the use of alternative agents, improved recovery times.

A detailed analysis of cases where pharmacogenomics guided anesthetic management is given below.

Case Study 1: Personalized Propofol Dosing

A 55-year-old female with a known polymorphism in the UGT1A9 gene, which results in reduced enzyme activity, was scheduled for elective surgery requiring general anesthesia. Preoperative genetic testing identified her as a poor metabolizer of propofol.

- *Management Plan:* The anesthesiologist adjusted the induction dose of propofol to a lower level and carefully monitored the depth of anesthesia. The infusion rate was titrated based on the patient's clinical response and genetic profile, ensuring adequate anesthesia while avoiding prolonged sedation [11].
- *Outcome:* The patient had a smooth induction and recovery, with no signs of delayed emergence. The use of personalized dosing based on pharmacogenomic data improved the safety and efficacy of the anesthetic regime.

Case Study 2: Opioid Metabolism and Pain Management

A 40-year-old male with a history of poor pain control after previous surgeries underwent genetic testing, which revealed he was a poor metabolizer of CYP2D6. This genotype suggested reduced conversion of codeine to morphine, explaining the inadequate pain relief with standard opioid regimens.

- *Management Plan:* For postoperative pain management, the anesthesiologist opted for hydromorphone, which does not rely on CYP2D6 for its metabolism. The dosing was adjusted based on the patient's genetic profile and pain assessment.
- *Outcome:* The patient experienced effective pain relief without significant side effects. Personalized pain management improved patient satisfaction and recovery.

Case Study 3: Managing Neuromuscular Blockade

A 65-year-old male with a known variant in the BCHE gene, resulting in reduced butyrylcholinesterase activity, required surgery with neuromuscular blockade. The patient's genetic profile indicated a risk for prolonged paralysis with succinylcholine.

- *Management Plan:* The anesthesiologist chose rocuronium instead of succinylcholine for muscle relaxation, with careful monitoring of neuromuscular function. Sugammadex was prepared for rapid reversal of rocuronium-induced blockade if necessary.
- *Outcome:* The patient had a stable intraoperative course with effective muscle relaxation and no prolonged paralysis postoperatively. The use of personalized neuromuscular blockade management improved safety and recovery.

Case Study 4: Fentanyl Sensitivity and Respiratory Depression

A 50-year-old female with a polymorphism in the CYP3A4 gene, associated with reduced enzyme activity, underwent surgery requiring opioid analgesia. Preoperative genetic testing suggested she might have increased sensitivity to fentanyl.

- *Management Plan:* The anesthesiologist used a lower initial dose of fentanyl and monitored respiratory function closely during and after surgery. Alternative pain management strategies, including multimodal analgesia with non-opioid agents, were also employed [12].
- *Outcome:* The patient had effective pain control with minimal opioid use and no episodes of respiratory depression. Personalized opioid dosing based on pharmacogenomic data enhanced safety and efficacy.

Case Study 5: Personalized Anti-Emetic Therapy

A 35-year-old female with a history of severe postoperative nausea and vomiting (PONV) after previous surgeries underwent genetic testing, which revealed polymorphisms in the HTR3A gene affecting the 5-HT3 receptor [13].

- *Management Plan:* The anesthesiologist chose a combination of antiemetic agents targeting different pathways, including dexamethasone and aprepitant, along with a lower dose of ondansetron tailored to the patient's genetic profile.
- *Outcome:* The patient experienced minimal PONV and smooth recovery. Personalized antiemetic therapy based on pharmacogenomic information improved postoperative comfort and satisfaction (Table 1) [14].

SUPPLEMENTARY

Appendix A: Detailed Table

Table 1. Common genetic polymorphisms in drug metabolizing enzymes.

Enzyme	Gene	Polymorphism	Allele Frequency	Clinical Implications
• CYP2 D6	• CYP2 D6	• *1/*2/*3/*4	• 10–20%	• Affects metabolism of opioids, beta-blockers.
• CYP2 C9	• CYP2 C9	• *2/*3	• 10–15%	• Impacts warfarin and NSAID metabolism.
• CYP2 C19	• CYP2 C19	• *2/*3	• 15–25%	• Influences proton pump inhibitors, clopidogrel.

A diagram illustrating the steps involved in integrating pharmacogenomic testing into clinical workflows, from sample collection to result interpretation and clinical decision is given in Figure 1.



Figure 1. Workflow of pharmacogenomic testing in clinical practice.



Figure 2. Mechanisms of drug metabolism by cytochrome P450 enzymes.

An infographic detailing the role of cytochrome P450 enzymes in the metabolism of various drugs, including the impact of genetic polymorphisms on enzyme activity is shown in Figure 2.

Appendix C: Protocols

Protocol C1: Preoperative genetic testing for anesthetic management

It is a step-by-step protocol for conducting preoperative genetic testing, including patient consent, sample collection, genetic analysis and interpretation of results for personalized anesthetic planning.

Protocol C2: Personalized dosing guidelines for common anesthetic agents.

It gives detailed guidelines for adjusting doses of common anesthetic agents based on genetic profiles, providing specific recommendations for volatile anesthetics, intravenous anesthetics, opioids, and neuromuscular blockers.

Appendix D: Case Studies

- *Case Study D1: Pharmacogenomic-Guided Anesthetic Management in a Patient with CYP2D6 Polymorphism*
  A comprehensive case study detailing the anesthetic management of a patient with a known CYP2D6 polymorphism, highlighting the use of pharmacogenomic data to tailor drug selection and dosing.
- *Case Study D2: Impact of Pharmacogenomic Testing on Postoperative Pain Management*
  An analysis of a case where pharmacogenomic testing informed postoperative pain management, resulting in improved pain control and reduced opioid-related side-effects.

Appendix E: Ethical Considerations

- *Ethical Guidelines for Genetic Testing in Anesthesia*
  A document outlining the ethical considerations and guidelines for conducting genetic testing in anesthesia, including issues related to patient consent, data privacy, and the potential for genetic discrimination.

By providing comprehensive references and supplementary materials, this research work offers a robust foundation for understanding and applying pharmacogenomics in anesthesia, ensuring that practitioners have access to the necessary tools and knowledge to implement personalized anesthetic care effectively.

CONCLUSIONS

Pharmacogenomics offers significant potential for optimizing analgesic therapies by aligning treatment plans with individual genetic profiles. While evidence regarding CYP2D6 polymorphisms supports targeted approaches, broader genetic screening for predicting drug responses and adverse effects remains premature. The intricate genetic factors influencing pain perception call for further research, including comprehensive sequencing and identification of rare mutations, to unlock the full potential of pharmacogenomics in clinical practice.

- *Advancing Personalized Medicine:* At the core of personalized medicine, pharmacogenomics empowers anesthesiologists to customize drug therapies based on genetic insights. This approach holds the promise of improving anesthetic drug safety and efficacy, minimizing adverse drug reactions, and enhancing patient outcomes.
- *Addressing Existing Challenges:* Despite notable advancements, challenges persist, including the high cost of genetic testing, lack of standardized guidelines, and ethical, legal, and logistical considerations. Overcoming these hurdles will require sustained research efforts, cross-disciplinary collaboration, and the establishment of supportive policies and frameworks.
- *Elevating Patient Care:* The aim of pharmacogenomics in anesthesiology is to elevate patient care by enabling precise and effective aesthetic management. By leveraging pharmacogenomic innovations, anesthesiology can pave the way for the widespread adoption of personalized medicine, delivering higher-quality care to surgical patients.

REFERENCES

1. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annu Rev Genomics Hum Genet. 2006;7:223–45. doi:10.1146/annurev.genom.6.080604.162315.
2. Meyer UA. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;5(9):669–76. doi:10.1038/nrg1428.

3. Flockhart DA. Cytochrome P450 Drug Interaction Table. Clin Pharmacol Ther. 2007;81(1):45–9.
4. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487–91. doi:10.1126/science.286.5439.487.
5. Voora D, McLeod HL, Eby C, Gage BF. The pharmacogenetics of coumarin therapy. Pharmacogenomics. 2005 Jul;6(5):503–13. doi:10.2217/14622416.6.5.503.
6. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55:89–106. doi:10.1146/annurev-pharmtox-010814-124835.
7. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med. 2011 Apr;78(4):243–57. doi:10.3949/ccjm.78a.10145.
8. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18):2270–9. doi:10.1001/jama.286.18.2270.
9. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol. 2001;41:101–21. doi:10.1146/annurev.pharmtox.41.1.101.
10. Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nat Rev Drug Discov. 2002;1(1):37–44. doi:10.1038/nrd705.
11. Ginsburg GS, Willard HF. Genomic and personalized medicine: Foundations and applications. Transl Res. 2009;154(6):277–87. doi:10.1016/j.trsl.2009.09.005.
12. Ahmad M, Abu Tabar N, Othman EH, Abdelrahim Z. Shared decision-making measures: A systematic review. Qual Manag Health Care. 2020 Apr–Jun;29(2):54–66. doi:10.1097/QMH.0000000000000250.
13. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–64. doi:10.1056/NEJMoa0809329.
14. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Derijks HJ, Brouwers JR, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73.

